Quantitative assessment of cerebral glucose metabolic rates after blood–brain barrier disruption induced by focused ultrasound using FDG-MicroPET

Yang, Feng; Chang, Wen Yuan; Chen, Jyh Cheng; Lee, Lin Chien; Hung, Yi Shun

doi:10.1016/j.neuroimage.2013.12.033

Cited by 30 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before scanning, each animal received a single dose of 18 FDG (1.8-2.0 mCi) via an intraperitoneal injection. The 18 FDG doses used are consistent with both intraperitoneal and intravenous doses reported previously using both rats/mice and microPET (Chen et al, 2010;Parthoens et al, 2014;Yang et al, 2014). Perhaps most importantly, however, 18 FDG doses were specifically designed to produce count rates that did not exceed the dead time correction capabilities of our scanner and images that could be reconstructed using an iterative method (ie, maximum a posteriori (MAP)).…”

Section: Methodsmentioning

confidence: 93%

Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement

Santoro

Carrion

Patel

et al. 2017

Neuropsychopharmacol

View full text Add to dashboard Cite

Methadone and buprenorphine are currently the most common pharmacological treatments for opioid dependence. Interestingly, the clinical response to these drugs appears to be sex specific. That is, females exhibit superior therapeutic efficacy, defined as extended periods of abstinence and longer time to relapse, compared with males. However, the underlying metabolic effects of opioid withdrawal and replacement have not been examined. Therefore, using FDG and microPET, we measured differences in regional brain glucose metabolism in males and females following morphine withdrawal and subsequent methadone or buprenorphine replacement. In both males and females, spontaneous opioid withdrawal altered glucose metabolism in regions associated with reward and drug dependence. Specifically, metabolic increases in the thalamus, as well as metabolic decreases in insular cortex and the periaqueductal gray, were noted. However, compared with males, females exhibited increased metabolism in the preoptic area, primary motor cortex, and the amygdala, and decreased metabolism in the caudate/putamen and medial geniculate nucleus. Methadone and buprenorphine initially abolished these changes uniformly, but subsequently produced their own regional metabolic alterations that varied by treatment and sex. Compared with sex-matched control animals undergoing spontaneous opioid withdrawal, male animals treated with methadone exhibited increased caudate/putamen metabolism, whereas buprenorphine produced increased ventral striatum and motor cortex metabolism in females, and increased ventral striatum and somatosensory cortex metabolism in males. Notably, when treatment effects were compared between sexes, methadone-treated females showed increased cingulate cortex metabolism, whereas buprenorphine-treated females showed decreased metabolism in cingulate cortex and increased metabolism in the globus pallidus. Perhaps the initial similarities in males and females underlie early therapeutic efficacy, whereas these posttreatment sex differences contribute to clinical treatment failure more commonly experienced by the former.

show abstract

Section: Methodsmentioning

confidence: 93%

Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement

Santoro

Carrion

Patel

et al. 2017

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…It has been shown that FUS-induced BBB disruption can be quantified based on the extravasation of EB 42 . Here, we used EB to evaluate the relationship between the dose of AlCl 3 administration and BBB integrity.…”

Section: Methodsmentioning

confidence: 99%

Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model

Lin

Chen

et al. 2015

Sci Rep

Self Cite

139

View full text Add to dashboard Cite

The protein expressions of neurotrophic factors can be enhanced by low-intensity pulsed ultrasound (LIPUS) stimulation in the brain. The purpose of this study was to demonstrate the protective effect of LIPUS stimulation against aluminum-induced cerebral damage in Alzheimer's disease rat model. LIPUS was administered 7 days before each aluminum chloride (AlCl3) administration, and concomitantly given with AlCl3 daily for a period of 6 weeks. Neurotrophic factors in hippocampus were measured by western blot analysis. Behavioral changes in the Morris water maze and elevated plus maze were examined in rats after administration of AlCl3. Various biochemical analyses were performed to evaluate the extent of brain damages. LIPUS is capable of prompting levels of brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) in rat brain. AlCl3 administration resulted in a significant increase in the aluminum concentration, acetylcholinesterase activity and beta-amyloid (Aβ) deposition in AlCl3 treated rats. LIPUS stimulation significantly attenuated aluminum concentration, acetylcholinesterase activity, Aβ deposition and karyopyknosis in AlCl3 treated rats. Furthermore, LIPUS significantly improved memory retention in AlCl3-induced memory impairment. These experimental results indicate that LIPUS has neuroprotective effects against AlCl3-induced cerebral damages and cognitive dysfunction.

show abstract

“…In addition, BBB permeability may also be increased by the activation of transcellular transport pathways . At the same time, FUS with microbubbles can induce neuromodulation of neuronal activity, decrease glucose uptake, trigger a sterile inflammatory response, and even produce behavioral alterations . These effects may occur in parallel to or as a consequence of the BBB opening.…”

Section: Bbb Opening To Halt Nigrostriatal Neurodegenerationmentioning

confidence: 99%

Focused ultrasound in Parkinson's disease: A twofold path toward disease modification

et al. 2019

View full text Add to dashboard Cite

A major unmet need in Parkinson's disease (PD) is to slow the inexorable progression of neurodegeneration. Clinical trials that evaluated promising pharmacological strategies have repeatedly failed. Nonetheless, the advent of focused ultrasound provides new opportunities toward the goal of developing a safe and effective disease‐modifying therapy for PD. Here we discuss the rationale, possible avenues, and challenges along this path, exploiting the potential of focused ultrasound for (1) performing focal thermal lesions to restore the basic basal ganglia abnormalities associated with dopamine depletion, and (2) transiently opening the blood–brain barrier for targeted delivery of therapeutic agents. First, the classic idea of excitotoxicity mediated by hyperactivity of the subthalamic nucleus suggests that focused ultrasound subthalamotomy may offer a clinically viable disease‐modifying therapy in very‐early PD. Second, the concept of retrograde nigrostriatal neurodegeneration, supported by our recent cortical pathogenic theory of PD, points toward the putamen as a principal site for focused ultrasound blood–brain barrier opening and targeted drug delivery. In principle, both therapeutic strategies—subthalamotomy and putaminal blood–brain barrier opening—could eventually be applied in the same patient. Clinical application is still a long road ahead; nevertheless, focused ultrasound may open a twofold path toward disease modification in PD. © 2019 International Parkinson and Movement Disorder Society

show abstract

Quantitative assessment of cerebral glucose metabolic rates after blood–brain barrier disruption induced by focused ultrasound using FDG-MicroPET

Cited by 30 publications

References 25 publications

Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement

Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement

Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model

Focused ultrasound in Parkinson's disease: A twofold path toward disease modification

Contact Info

Product

Resources

About